NASDAQ:SY So-Young International Q1 2024 Earnings Report $0.84 +0.00 (+0.13%) Closing price 05/5/2025 03:58 PM EasternExtended Trading$0.84 +0.00 (+0.11%) As of 05/5/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast So-Young International EPS ResultsActual EPS-$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASo-Young International Revenue ResultsActual Revenue$44.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASo-Young International Announcement DetailsQuarterQ1 2024Date5/28/2024TimeBefore Market OpensConference Call DateTuesday, May 28, 2024Conference Call Time7:30AM ETUpcoming EarningsSo-Young International's Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled at 7:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Earnings HistoryCompany ProfilePowered by So-Young International Q1 2024 Earnings Call TranscriptProvided by QuartrMay 28, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Ladies and gentlemen, thank you for standing by for Sohyoung's First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen only mode. After management give their prepared remarks, there will be an opportunity for question and answers. As a reminder, today's conference is being recorded. I would now like to turn the conference over to your host for today's call, Ms. Operator00:00:24Mona Chiao. Please go ahead, ma'am. Speaker 100:00:29Thank you, operator, and thank you, everyone, for joining Sogoung's Q1 2024 Earnings Conference Call. Joining me today on the call is Mr. Xin Jin, our Co Founder, Chairman and CEO and Mr. Nick Zhao, CFO. Please note that the discussion today will contain forward looking statements made under the Safe Harbor provisions of the U. Speaker 100:00:49S. Private Securities and the Litigation Reform Act of 1995. Forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but are not limited to, those outlined in our public filings with SEC, including our Annual Report on Form 20 F. Sohyang does not undertake any obligation to update any forward looking statements except as required under applicable law. Speaker 100:01:20At this time, I would like to turn the call over to Mr. Xin Jin. Hello, everyone. Thank you for joining the call today. Our business performed well in the Q4 with total revenues reaching RMB318.3 million, exceeding the upper end of our guidance. Speaker 100:02:15At the same time, this marks the first time in 5 years that we achieved non GAAP profitability in the 4th quarter. Our new businesses continue to grow rapidly with revenue from services medical products and maternity services increased 23.3% year over year. Our pipeline of upstream products continues to further diversify its offerings, while Sohuang Fuem maintained healthy development. We have made significant progress in the expansion of our chain of clinics. In the Q1, we opened and began operations at 3 clinics, all of which boost unit area efficiencies well above industry average at a notable price advantage. Speaker 100:03:48In the Q1, the cumulative clients serviced by our clinics increased 77% quarter over quarter. We've also made steady headway of vertical integration from products to institutions, driving and value allocation in the industry. This will provide consumers with medical aesthetic services that are more cost efficient and help with sustainable development of medical aesthetic practitioners. In terms of products, institutions and Sohyang platform, As we made steady progress in these initiatives, we are confident in the growth opportunities for us going forward. In our Pop segment, we continued to advantage our differentiated strategy to solidify our advantage within the premium segments of the market. Speaker 100:05:36By offering customized and high value services, we are not only able to serve high end users, but also assist institutions in boosting their profits. During the quarter, our order value increased by 11.3% year over year. In terms of traffic acquisition, we reallocated our budget away from low ROI online channels and instead focused on cultivating and returning a target user base within our private domains. We leveraged various channels within and outside of the Soyan platform and improved user engagement, aiming to enhance our monetization efficiency. As a result, in the Q4, users required through private domains increased by 19.7% quarter over quarter. Speaker 100:07:20Turning to Sohuang Shrine, we capitalized on the success of the model clinic we opened at our headquarters in Beijing in the later half of twenty twenty three. Building upon this momentum, we accelerated our strategy transition from partner institutions towards establishing a chain of clinics. During the quarter, we opened 3 clinics with operations firmly on track. By the end of this month, we expect to open at commence operations for our 3rd batch of clinics. To efficiently drive this transition, we have established a comprehensive and standardized workflow system, covering everything from site selection and evaluation to clinic opening and operations. Speaker 100:08:04This has enabled us to expand at a pace that significantly surpasses the industry average and set an industry record for the rollout of new clinics. We plan to expand our chain of clinics nationwide, starting with 5 to 6 core cities. At the same time, Sohyang Prime continues to garner exceptionally high with user satisfaction of over 4.9 out of 5 for each institution every month at an ever increasing repurchase rate. Lastly, I will provide a quick recap of the process we have made in our upstream supply chain business. Sales of the Korea brand Rovi continued to grow strongly over the quarter, increasing 80% year over year. Speaker 100:09:38In just 1 year, we have established a mature distribution network that covers 750 institutions through both direct and agency sales channels. Our recent launch of Tru Lift in non surgical anti aging ultrasound device has further diversified our product portfolio with sales far exceeding expectations. The success of this product is a testament to the strength of our brand, Word-of-mouth recognition among consumers and the domestic's whole variable to quickly bring new products to market and rapidly secure their market position through our expansive institutional network. We recognize the immense potential for growth in China's medical aesthetics market. However, the industry still contends with a less than favorable public perception despite its development over the past 2 decades. Speaker 100:11:20While a injection that caused tons of RMB can be sold for solvent, many institutions within this sector struggle to turn a profit. Realities such as this point to structural issues. Sohyang will address these issues by establishing an industry platform. By integrating the upstream, midstream and downstream resources of the medical aesthetic industry, we aim to fundamentally reduce cost and increase efficiency and provide consumers with better and more cost effective medical aesthetic services. This approach is designed to drive sustainable revenue and profit growth for the platform, while ultimately delivering greater long term value to our shareholders. Speaker 100:12:14I will now turn the call over to our CFO, Nick, to review the financial results for this quarter before taking your questions. Speaker 200:12:23Hello, this is Nick. Please be reminded that all amounts quoted here will be in RMB. Please also refer to our earnings release for detailed information of our comparative financial performances on a year over year basis. Total revenues during the quarter were RMB318.3 million, up 2.6% year over year, exceeding the high end of our guidance. Growth was primarily driven by sales of medical products and maintenance services, which increased 23.3% year over year to RMB86.5 million, driven by the sales volumes increase of cosmetic products and medical equipment. Speaker 200:13:05Information services and other revenues were RMB208.7 million, a slight decrease of 0.7% year over year. Reservation service revenues decreased 22.3% year over year to RMB23.1 million, primarily due to the policy change for commission rates and subsidies. Cost of revenues were RMB117.3 million, up 3.2% year over year, primarily due to increased costs associated with the sales of cosmetic products and medical equipment. Within cost of revenues, cost of services and others were RMB74.2 million, down 8.9% year over year, primarily due to a decrease in payroll costs. Cost of medical products sold and maintenance services were RMB43.1 million, up 33.7% year over year, primarily due to an increase in costs associated with the sales of cosmetic products and medical equipment. Speaker 200:14:19Total operating expenses were RMB237.8 million, up 3.5 percent year over year. Sales and marketing expenses were RMB113.3 million, up 0.7% year over year, primarily due to an increase in payroll costs associated with the expansion of our marketing team. G and A expenses were RMB85 1,000,000, up 38.1 percent year over year, primarily due to an increase in payroll costs associated with the expansion of the administrative employees to support the enhancement of our core and new strategic businesses. R and D expenses were RMB39.6 1,000,000, down 29% year over year, primarily attributable to improvements in employee efficiency. Income tax benefits were RMB2.6 million compared with income tax benefits of RMB4.3 4,300,000 in the same period of 2023. Speaker 200:15:28Net loss attributable to Sohyang was RMB21.2 million compared with a net loss of RMB11.9 million during the same period last year. Net non GAAP net income attributable to Sohyoung was RMB4.1 million compared with RMB2.8 RMB2.8 million net non GAAP net loss attributable to Sohyang in the same period of 2023. Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.21 and RMB0.21, compared with basic and diluted losses per ADS attributable to ordinary shareholders of RMB0.12 and RMB0.12, respectively, during the same period of 2023. We have maintained a robust cash position with cash and cash equivalents, restricted cash and term deposits, term deposits and short term investments totaling RMB1.3 billion as of March 31, 2024, effectively flat when compared with December 31, 2023. For the Q2 of 2024, we expect total revenues to be between RMB380 1,000,000 and RMB400 1,000,000. Speaker 200:16:53The above outlook is based on the current market conditions that reflects the company's preliminary estimates of market and operating conditions and the customer demand. This concludes our key remarks. I will now turn the call to the operator and open the call for Q and A. Operator, we are ready to take questions. Operator00:17:19Thank you, sir. Ladies and gentlemen, we will now begin the question and answer session. The first question we have comes from Chloe Wei of CICC. Please go ahead. Speaker 300:18:18So let me translate myself. Thanks management for taking my question. Congrats on the solid first quarter results. The top line well ahead of our expectation. So my question is about the full year outlook. Speaker 300:18:31From what we got from the prepared remarks, I believe our time have turned more positive. So is there some trend and maybe management want to share with us? And given the headwinds from the macro, how should we think about our full year top line growth? Thank you. Speaker 100:19:33Development of medical aesthetics industry in the Q1 is in line with our observation and expectation at the beginning of the year. First, the Chinese medical aesthetics market is gradually recovering with the overall consumption market. As retail sales of consumer goods in China increased by 4.7% year over year in the Q4, medical aesthetics consumption data has also reflected a gradual growth trade. 2nd, as the medical aesthetics user group tends to mature, user demands are more diversified. It's difficult to attract high quality clients simply with low prices. Speaker 100:20:12More enriched products and services are required to cater to differentiated user demand. In 2024, we will maintain our strategies based on our existing business. We will establish a platform that vertically integrates upstream supply chains, midstream operations and downstream distribution channels to fundamentally optimize costs and enhance efficiency. This strategy approach will enable us to deliver superior and more cost effective services to consumers. Operator00:21:16The next question we have comes from He Jian Peng of CITIC Securities. Please go ahead. Speaker 400:21:49So, okay, thanks for this opportunity. Just two questions. First is, how to consider the decline of the traditional metrics such as MAU And what's the business difference advantages in this intensified traffic competition yet? Thank you. Speaker 100:23:18In terms of online traffic, all industries are experiencing intensified competition for traffic. For Sohuang app, we continue to boost engagement and attract more organic user traffic through operation of community content and self media resources. In addition, through extensive private domain operations, we strive to connect Sohyang app with private domains, expanding its traffic pool as we increase private domain retention rate and user engagements. This part of data is not reflected in our MAU, But judging from recent transition data such as GMV and online orders, it reflects it has remained basically stable. It is meant to the effectiveness of this strategy. Speaker 100:24:06It can also help lower traffic costs and enhance profits. Thirdly, in terms of cooperation with 3rd party traffic sources, we emphasize our traffic accuracy and placement ROI, reduce budget for channels with low ROI to further reduce placement costs and increase margins survival Speaker 200:24:28platform. Speaker 100:25:24Compared to our peers, we have 2 core efficiencies advantage. First, we have high quality users and a high average order value. 2nd, we benefit from our own offline medical aesthetic institutions, including Sohuang, Qing Clinics and shared hospitals, which provide us with greater room for innovation. For surgical customers, we organize offline consultations and invite multiple renowned doctors to participate. Centralized consultations help users save time and transportation costs and face to face communication also improves users' decision making efficiency. Speaker 100:26:05For high end injection customers, we screen high quality doctors on the platform and complete service deliveries within our own or cooperative institutions. With this approach, we have stronger control over the contract for fulfillment and delivery process, while simultaneously commanding price power and conducting refined user operations in a closed loop manner, thus avoiding the risk of Operator00:26:36user attrition. Thank you. The next question we have comes from Yi Bing of Haitong. Please go ahead. Speaker 500:27:07Okay. Thanks for management. I'll translate myself. My question is about the Soryong Prime. I want to ask is the current progress of the opening new clinics on the Sohyang Prime in line with your expectation? Speaker 500:27:24And what's your midterm to long term plans for a proprietary chain clinics? Thank you. Speaker 100:28:05We plan to open 15 clinics in 2024 at the beginning of the year. By the end of the Q4, we opened 3 clinics. Since then, we added 2 more before today's earnings. Now we are opening 6 clinics in all, generally in line with our expectation. During the process, we have established a comprehensive and centralized workflow system covering everything from site selection and evaluation to client opening and operations. Speaker 100:28:34This has enabled us to expand at a pace that significantly surpasses industry average and set our industry record for the rule out of new clinics. Emphasizing on authentic products, cost performance and transparency, our aim is to position standardized light medical aesthetical services as the 4th choice of everyday cosmetic conception. We expect to reach the scale of 100 to 150 clinics in the next Speaker 400:29:243 years. Speaker 100:30:02While expanding our chain of clinics, we continue to build our operation team, combining our advantage in product supply, development and innovation. We are driving to build out of a standardized management system for life medical aesthetics institutions as well as an end to end online process management capabilities to improve operating and management efficiency for institutions. In the future, we will continue to improve efficiency per staff and efficiency per unit area for our chain of clinics, increase penetration of our proprietary supply chain products, improve margin of our chain clinics while providing users with more cost effective services. User satisfaction is fundamental to chain operation. With that in mind, we emphasize more on user satisfaction. Speaker 100:31:13From January to April, user satisfaction in our chain of clinics reached 98% and in line with our expectations. Thank you. Operator00:31:25The next question we have comes from Joey Tan of Jefferies. Please go ahead. Speaker 300:31:54Thank you for the management for taking my question. And I have two questions. The first question is, could management share on new progress for upstream supply chain business? And the second question is with the cash reserve of progressing asset, RMB 1,300,000,000 with such a complaint and usage? Thank you. Speaker 100:32:47On product side, sales are already maintained strong momentum with sales increasing 80% year over year and revenue increased 56.5% year over year in the 4th quarter. In addition, we spent just 1 year to establish a mature distribution network covering 7 15 institutions, they were both direct and agencies of channels. In the future, we will continue to integrate our upstream supply chain, help companies to increase profit and return to users with products of sound cost performance, reaching win win situation. 2nd, we continue to expand our product pipeline. The launch of facelift product, Tru Lift, further diversifies our photoelectric category with sales far exceeding expectations. Speaker 100:34:15This is brand, watermark recognition among consumers as domesticates how we are able to quickly bring new products to market and rapidly secure their market position through our extensive institutional network. We expect to add more products and continuously generate incremental revenue and profit growth from the supply chain business. Speaker 200:35:22I will translate. We will use the cash for two purposes. First of all, we will continue expanding along upstream and downstream of the industry, including upstream product pipeline and downstream chain of clinics to lay solid ground for our integrated industry platform. And secondly, we will share repurchase plan or potential dividend to return values to our shareholders. Thank you. Operator00:35:56Thank you, sir. Ladies and gentlemen, we have reached the end of our question and answer session and our conference.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallSo-Young International Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K) So-Young International Earnings HeadlinesSo-Young to Report First Quarter 2025 Financial Results on May 16, 2025May 6 at 5:00 AM | prnewswire.comSo-Young International Inc. Files Its Annual Report on Form 20-FApril 18, 2025 | gurufocus.comOur $1 AI stock to buy right nowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.May 6, 2025 | Behind the Markets (Ad)So-Young International Inc. Files Its Annual Report on Form 20-F | SY Stock NewsApril 18, 2025 | gurufocus.comSo-Young International Inc. Files Its Annual Report on Form 20-FApril 18, 2025 | prnewswire.comSo-Young controlling shareholder purchases $4.09M in sharesApril 2, 2025 | markets.businessinsider.comSee More So-Young International Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like So-Young International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on So-Young International and other key companies, straight to your email. Email Address About So-Young InternationalSo-Young International (NASDAQ:SY) operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users medical aesthetic knowledge and experience to reach an informed medical aesthetic treatment decision and make reservations for treatment with medical professionals and medical aesthetic institutions; So-Young Beauty which provides similar interfaces and functions as the mobile app, as well as serves as additional access points to the platform; and medical aesthetic community content through its website soyoung.com. It provides content in various media formats on its online platform generated by users, including professional generated, content from in-house editorial team that shares opinions on specific new medical procedures and trends; user generated content comprising Beauty Diaries that provides details about medical institution, doctor, price, and other information on the treatment; professional user generated, contents from the medical aesthetic influencers; and doctor generated, content from doctors to generate knowledge. In addition, the company offers consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and software as a service. Further, it engages in research and development, production, sales, and agency of laser and other optoelectronic medical beauty equipment; manufacture and sells light therapy device, surgical laser device and other equipment; internet information and technology advisory; online medical treatment and consultation; management consulting; internet culture; micro finance services, as well as sells cosmetics products. The company was founded in 2013 and is headquartered in Beijing, China.View So-Young International ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Upcoming Earnings Fortinet (5/7/2025)ARM (5/7/2025)DoorDash (5/7/2025)AppLovin (5/7/2025)MercadoLibre (5/7/2025)Lloyds Banking Group (5/7/2025)Manulife Financial (5/7/2025)Novo Nordisk A/S (5/7/2025)Uber Technologies (5/7/2025)Johnson Controls International (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Ladies and gentlemen, thank you for standing by for Sohyoung's First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen only mode. After management give their prepared remarks, there will be an opportunity for question and answers. As a reminder, today's conference is being recorded. I would now like to turn the conference over to your host for today's call, Ms. Operator00:00:24Mona Chiao. Please go ahead, ma'am. Speaker 100:00:29Thank you, operator, and thank you, everyone, for joining Sogoung's Q1 2024 Earnings Conference Call. Joining me today on the call is Mr. Xin Jin, our Co Founder, Chairman and CEO and Mr. Nick Zhao, CFO. Please note that the discussion today will contain forward looking statements made under the Safe Harbor provisions of the U. Speaker 100:00:49S. Private Securities and the Litigation Reform Act of 1995. Forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but are not limited to, those outlined in our public filings with SEC, including our Annual Report on Form 20 F. Sohyang does not undertake any obligation to update any forward looking statements except as required under applicable law. Speaker 100:01:20At this time, I would like to turn the call over to Mr. Xin Jin. Hello, everyone. Thank you for joining the call today. Our business performed well in the Q4 with total revenues reaching RMB318.3 million, exceeding the upper end of our guidance. Speaker 100:02:15At the same time, this marks the first time in 5 years that we achieved non GAAP profitability in the 4th quarter. Our new businesses continue to grow rapidly with revenue from services medical products and maternity services increased 23.3% year over year. Our pipeline of upstream products continues to further diversify its offerings, while Sohuang Fuem maintained healthy development. We have made significant progress in the expansion of our chain of clinics. In the Q1, we opened and began operations at 3 clinics, all of which boost unit area efficiencies well above industry average at a notable price advantage. Speaker 100:03:48In the Q1, the cumulative clients serviced by our clinics increased 77% quarter over quarter. We've also made steady headway of vertical integration from products to institutions, driving and value allocation in the industry. This will provide consumers with medical aesthetic services that are more cost efficient and help with sustainable development of medical aesthetic practitioners. In terms of products, institutions and Sohyang platform, As we made steady progress in these initiatives, we are confident in the growth opportunities for us going forward. In our Pop segment, we continued to advantage our differentiated strategy to solidify our advantage within the premium segments of the market. Speaker 100:05:36By offering customized and high value services, we are not only able to serve high end users, but also assist institutions in boosting their profits. During the quarter, our order value increased by 11.3% year over year. In terms of traffic acquisition, we reallocated our budget away from low ROI online channels and instead focused on cultivating and returning a target user base within our private domains. We leveraged various channels within and outside of the Soyan platform and improved user engagement, aiming to enhance our monetization efficiency. As a result, in the Q4, users required through private domains increased by 19.7% quarter over quarter. Speaker 100:07:20Turning to Sohuang Shrine, we capitalized on the success of the model clinic we opened at our headquarters in Beijing in the later half of twenty twenty three. Building upon this momentum, we accelerated our strategy transition from partner institutions towards establishing a chain of clinics. During the quarter, we opened 3 clinics with operations firmly on track. By the end of this month, we expect to open at commence operations for our 3rd batch of clinics. To efficiently drive this transition, we have established a comprehensive and standardized workflow system, covering everything from site selection and evaluation to clinic opening and operations. Speaker 100:08:04This has enabled us to expand at a pace that significantly surpasses the industry average and set an industry record for the rollout of new clinics. We plan to expand our chain of clinics nationwide, starting with 5 to 6 core cities. At the same time, Sohyang Prime continues to garner exceptionally high with user satisfaction of over 4.9 out of 5 for each institution every month at an ever increasing repurchase rate. Lastly, I will provide a quick recap of the process we have made in our upstream supply chain business. Sales of the Korea brand Rovi continued to grow strongly over the quarter, increasing 80% year over year. Speaker 100:09:38In just 1 year, we have established a mature distribution network that covers 750 institutions through both direct and agency sales channels. Our recent launch of Tru Lift in non surgical anti aging ultrasound device has further diversified our product portfolio with sales far exceeding expectations. The success of this product is a testament to the strength of our brand, Word-of-mouth recognition among consumers and the domestic's whole variable to quickly bring new products to market and rapidly secure their market position through our expansive institutional network. We recognize the immense potential for growth in China's medical aesthetics market. However, the industry still contends with a less than favorable public perception despite its development over the past 2 decades. Speaker 100:11:20While a injection that caused tons of RMB can be sold for solvent, many institutions within this sector struggle to turn a profit. Realities such as this point to structural issues. Sohyang will address these issues by establishing an industry platform. By integrating the upstream, midstream and downstream resources of the medical aesthetic industry, we aim to fundamentally reduce cost and increase efficiency and provide consumers with better and more cost effective medical aesthetic services. This approach is designed to drive sustainable revenue and profit growth for the platform, while ultimately delivering greater long term value to our shareholders. Speaker 100:12:14I will now turn the call over to our CFO, Nick, to review the financial results for this quarter before taking your questions. Speaker 200:12:23Hello, this is Nick. Please be reminded that all amounts quoted here will be in RMB. Please also refer to our earnings release for detailed information of our comparative financial performances on a year over year basis. Total revenues during the quarter were RMB318.3 million, up 2.6% year over year, exceeding the high end of our guidance. Growth was primarily driven by sales of medical products and maintenance services, which increased 23.3% year over year to RMB86.5 million, driven by the sales volumes increase of cosmetic products and medical equipment. Speaker 200:13:05Information services and other revenues were RMB208.7 million, a slight decrease of 0.7% year over year. Reservation service revenues decreased 22.3% year over year to RMB23.1 million, primarily due to the policy change for commission rates and subsidies. Cost of revenues were RMB117.3 million, up 3.2% year over year, primarily due to increased costs associated with the sales of cosmetic products and medical equipment. Within cost of revenues, cost of services and others were RMB74.2 million, down 8.9% year over year, primarily due to a decrease in payroll costs. Cost of medical products sold and maintenance services were RMB43.1 million, up 33.7% year over year, primarily due to an increase in costs associated with the sales of cosmetic products and medical equipment. Speaker 200:14:19Total operating expenses were RMB237.8 million, up 3.5 percent year over year. Sales and marketing expenses were RMB113.3 million, up 0.7% year over year, primarily due to an increase in payroll costs associated with the expansion of our marketing team. G and A expenses were RMB85 1,000,000, up 38.1 percent year over year, primarily due to an increase in payroll costs associated with the expansion of the administrative employees to support the enhancement of our core and new strategic businesses. R and D expenses were RMB39.6 1,000,000, down 29% year over year, primarily attributable to improvements in employee efficiency. Income tax benefits were RMB2.6 million compared with income tax benefits of RMB4.3 4,300,000 in the same period of 2023. Speaker 200:15:28Net loss attributable to Sohyang was RMB21.2 million compared with a net loss of RMB11.9 million during the same period last year. Net non GAAP net income attributable to Sohyoung was RMB4.1 million compared with RMB2.8 RMB2.8 million net non GAAP net loss attributable to Sohyang in the same period of 2023. Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.21 and RMB0.21, compared with basic and diluted losses per ADS attributable to ordinary shareholders of RMB0.12 and RMB0.12, respectively, during the same period of 2023. We have maintained a robust cash position with cash and cash equivalents, restricted cash and term deposits, term deposits and short term investments totaling RMB1.3 billion as of March 31, 2024, effectively flat when compared with December 31, 2023. For the Q2 of 2024, we expect total revenues to be between RMB380 1,000,000 and RMB400 1,000,000. Speaker 200:16:53The above outlook is based on the current market conditions that reflects the company's preliminary estimates of market and operating conditions and the customer demand. This concludes our key remarks. I will now turn the call to the operator and open the call for Q and A. Operator, we are ready to take questions. Operator00:17:19Thank you, sir. Ladies and gentlemen, we will now begin the question and answer session. The first question we have comes from Chloe Wei of CICC. Please go ahead. Speaker 300:18:18So let me translate myself. Thanks management for taking my question. Congrats on the solid first quarter results. The top line well ahead of our expectation. So my question is about the full year outlook. Speaker 300:18:31From what we got from the prepared remarks, I believe our time have turned more positive. So is there some trend and maybe management want to share with us? And given the headwinds from the macro, how should we think about our full year top line growth? Thank you. Speaker 100:19:33Development of medical aesthetics industry in the Q1 is in line with our observation and expectation at the beginning of the year. First, the Chinese medical aesthetics market is gradually recovering with the overall consumption market. As retail sales of consumer goods in China increased by 4.7% year over year in the Q4, medical aesthetics consumption data has also reflected a gradual growth trade. 2nd, as the medical aesthetics user group tends to mature, user demands are more diversified. It's difficult to attract high quality clients simply with low prices. Speaker 100:20:12More enriched products and services are required to cater to differentiated user demand. In 2024, we will maintain our strategies based on our existing business. We will establish a platform that vertically integrates upstream supply chains, midstream operations and downstream distribution channels to fundamentally optimize costs and enhance efficiency. This strategy approach will enable us to deliver superior and more cost effective services to consumers. Operator00:21:16The next question we have comes from He Jian Peng of CITIC Securities. Please go ahead. Speaker 400:21:49So, okay, thanks for this opportunity. Just two questions. First is, how to consider the decline of the traditional metrics such as MAU And what's the business difference advantages in this intensified traffic competition yet? Thank you. Speaker 100:23:18In terms of online traffic, all industries are experiencing intensified competition for traffic. For Sohuang app, we continue to boost engagement and attract more organic user traffic through operation of community content and self media resources. In addition, through extensive private domain operations, we strive to connect Sohyang app with private domains, expanding its traffic pool as we increase private domain retention rate and user engagements. This part of data is not reflected in our MAU, But judging from recent transition data such as GMV and online orders, it reflects it has remained basically stable. It is meant to the effectiveness of this strategy. Speaker 100:24:06It can also help lower traffic costs and enhance profits. Thirdly, in terms of cooperation with 3rd party traffic sources, we emphasize our traffic accuracy and placement ROI, reduce budget for channels with low ROI to further reduce placement costs and increase margins survival Speaker 200:24:28platform. Speaker 100:25:24Compared to our peers, we have 2 core efficiencies advantage. First, we have high quality users and a high average order value. 2nd, we benefit from our own offline medical aesthetic institutions, including Sohuang, Qing Clinics and shared hospitals, which provide us with greater room for innovation. For surgical customers, we organize offline consultations and invite multiple renowned doctors to participate. Centralized consultations help users save time and transportation costs and face to face communication also improves users' decision making efficiency. Speaker 100:26:05For high end injection customers, we screen high quality doctors on the platform and complete service deliveries within our own or cooperative institutions. With this approach, we have stronger control over the contract for fulfillment and delivery process, while simultaneously commanding price power and conducting refined user operations in a closed loop manner, thus avoiding the risk of Operator00:26:36user attrition. Thank you. The next question we have comes from Yi Bing of Haitong. Please go ahead. Speaker 500:27:07Okay. Thanks for management. I'll translate myself. My question is about the Soryong Prime. I want to ask is the current progress of the opening new clinics on the Sohyang Prime in line with your expectation? Speaker 500:27:24And what's your midterm to long term plans for a proprietary chain clinics? Thank you. Speaker 100:28:05We plan to open 15 clinics in 2024 at the beginning of the year. By the end of the Q4, we opened 3 clinics. Since then, we added 2 more before today's earnings. Now we are opening 6 clinics in all, generally in line with our expectation. During the process, we have established a comprehensive and centralized workflow system covering everything from site selection and evaluation to client opening and operations. Speaker 100:28:34This has enabled us to expand at a pace that significantly surpasses industry average and set our industry record for the rule out of new clinics. Emphasizing on authentic products, cost performance and transparency, our aim is to position standardized light medical aesthetical services as the 4th choice of everyday cosmetic conception. We expect to reach the scale of 100 to 150 clinics in the next Speaker 400:29:243 years. Speaker 100:30:02While expanding our chain of clinics, we continue to build our operation team, combining our advantage in product supply, development and innovation. We are driving to build out of a standardized management system for life medical aesthetics institutions as well as an end to end online process management capabilities to improve operating and management efficiency for institutions. In the future, we will continue to improve efficiency per staff and efficiency per unit area for our chain of clinics, increase penetration of our proprietary supply chain products, improve margin of our chain clinics while providing users with more cost effective services. User satisfaction is fundamental to chain operation. With that in mind, we emphasize more on user satisfaction. Speaker 100:31:13From January to April, user satisfaction in our chain of clinics reached 98% and in line with our expectations. Thank you. Operator00:31:25The next question we have comes from Joey Tan of Jefferies. Please go ahead. Speaker 300:31:54Thank you for the management for taking my question. And I have two questions. The first question is, could management share on new progress for upstream supply chain business? And the second question is with the cash reserve of progressing asset, RMB 1,300,000,000 with such a complaint and usage? Thank you. Speaker 100:32:47On product side, sales are already maintained strong momentum with sales increasing 80% year over year and revenue increased 56.5% year over year in the 4th quarter. In addition, we spent just 1 year to establish a mature distribution network covering 7 15 institutions, they were both direct and agencies of channels. In the future, we will continue to integrate our upstream supply chain, help companies to increase profit and return to users with products of sound cost performance, reaching win win situation. 2nd, we continue to expand our product pipeline. The launch of facelift product, Tru Lift, further diversifies our photoelectric category with sales far exceeding expectations. Speaker 100:34:15This is brand, watermark recognition among consumers as domesticates how we are able to quickly bring new products to market and rapidly secure their market position through our extensive institutional network. We expect to add more products and continuously generate incremental revenue and profit growth from the supply chain business. Speaker 200:35:22I will translate. We will use the cash for two purposes. First of all, we will continue expanding along upstream and downstream of the industry, including upstream product pipeline and downstream chain of clinics to lay solid ground for our integrated industry platform. And secondly, we will share repurchase plan or potential dividend to return values to our shareholders. Thank you. Operator00:35:56Thank you, sir. Ladies and gentlemen, we have reached the end of our question and answer session and our conference.Read morePowered by